AHA Issues Roadmap for Treating Heart Failure in Adults Over 65
A new AHA scientific statement outlines evidence-based strategies to optimize heart failure care for older adults navigating frailty, polypharmacy, and multimorbidity.
Summary
Heart failure disproportionately burdens adults over 65, yet this group is often underrepresented in major clinical trials and faces unique barriers to guideline-directed therapy. A new scientific statement from the American Heart Association addresses this gap directly, reviewing the evidence for standard heart failure treatments in older patients and providing a structured framework for clinicians. The statement covers how to manage complex cases involving multiple chronic conditions, polypharmacy risks, frailty, and social determinants of health. It emphasizes shared decision-making and benefit-to-risk assessment tailored to each patient. Practical implementation strategies and health system tools are also highlighted to help bridge the gap between evidence and real-world care for this high-risk population.
Detailed Summary
Heart failure is a growing public health crisis, and older adults bear a disproportionate share of its burden. Despite this, patients over 65 are frequently underrepresented in the landmark clinical trials that shape treatment guidelines. This creates a critical knowledge gap: clinicians must make high-stakes decisions for their most vulnerable patients using evidence derived largely from younger, healthier populations.
The American Heart Association convened a multidisciplinary expert panel to address this challenge head-on. The resulting scientific statement reviews the existing literature on heart failure care optimization specifically in adults aged 65 and older, synthesizing evidence on guideline-directed medical therapies and their applicability to this age group.
A central finding is that guideline-directed therapies for heart failure — including foundational drug classes — demonstrate consistent treatment effects and acceptable safety profiles even in older adults, supporting their use in this population. However, the statement acknowledges that successful implementation requires navigating complex barriers, including polypharmacy, frailty, cognitive impairment, and unmet social needs.
To address these challenges, the statement introduces a structured clinical framework that weighs benefit-to-risk ratios in the context of multimorbidity and social circumstances. It emphasizes shared decision-making as a cornerstone of care, ensuring that treatment plans align with individual patient goals and values. Practical guidance is offered for patients with advanced comorbidities who fall outside typical trial eligibility criteria.
The statement also highlights health system-level interventions and supportive tools — from care coordination programs to digital health technologies — that can help translate evidence into practice. Clinicians and health systems alike are encouraged to adopt these strategies to reduce morbidity and improve outcomes. Caveats include reliance on existing trial data that may not fully reflect older, frailer patients.
Key Findings
- Guideline-directed heart failure therapies show consistent efficacy and safety in adults over 65, supporting their broader use.
- Frailty, polypharmacy, and multimorbidity require individualized benefit-to-risk frameworks when prescribing heart failure medications.
- Shared decision-making is essential for aligning treatment intensity with the goals and values of older patients.
- Health system interventions and care coordination tools can help close the gap between evidence and real-world care.
- Older adults with advanced comorbidities are underrepresented in landmark trials, requiring extrapolation of evidence.
Methodology
This is a scientific statement from the American Heart Association, representing a comprehensive narrative review and expert synthesis of the existing literature on heart failure care in adults aged 65 and older. It does not represent a systematic review or meta-analysis with formal pooled statistics. Expert consensus was used to develop the clinical framework and practical recommendations.
Study Limitations
The summary is based on the abstract only, as the full text is not open access. The statement relies on existing trial evidence, much of which underrepresents older and frailer patients, limiting the strength of some recommendations. As a narrative expert review rather than a systematic meta-analysis, it carries inherent potential for selection bias in evidence synthesis.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.